Nanoscope Therapeutics, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Recruiting
- Conditions
- Macular DegenerationGeographic AtrophyStargardt Disease
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06805474
- Locations
- ๐บ๐ธ
Retina of North Texas,, Dallas, Texas, United States
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Active, not recruiting
- Conditions
- RetinitisRetinitis PigmentosaRetinal DiseasesEye Diseases, HereditaryRetinal DystrophiesRetinal DegenerationEye Diseases
- Interventions
- Biological: Gene Therapy product-MCO-010
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06162585
- Locations
- ๐ต๐ท
Nanoscope Clinical Site, Arecibo, Puerto Rico
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Active, not recruiting
- Conditions
- Stargardt Disease
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06048185
- Locations
- ๐บ๐ธ
Nanocope Clnical Site, Miami, Florida, United States
๐บ๐ธNanoscope Clinical Site, McAllen, Texas, United States
A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection
- Conditions
- Retinal DiseaseRetinitis PigmentosaRetinal Degeneration
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05921162
- Locations
- ๐ฎ๐ณ
JPM Rotary Club of Cuttack Eye Hospital and Research Institute, Cuttack, Odisha, India
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
Completed
- Conditions
- Retinitis PigmentosaRetinal Dystrophy
- Interventions
- Other: Observational
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05820100
- Locations
- ๐ต๐ท
Nanoscope Clinical Site, Arecibo, Puerto Rico
๐บ๐ธNanoscope Clincal Site, San Antonio, Texas, United States
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
Phase 2
Completed
- Conditions
- Stargardt Disease
- Interventions
- Biological: Gene Therapy-vMCO-010
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05417126
- Locations
- ๐บ๐ธ
Nanoscope Clinical Site, McAllen, Texas, United States
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Phase 2
Completed
- Conditions
- Eye Diseases, HereditaryRetinal DegenerationRetinal DiseasesRetinal DystrophiesRetinitis PigmentosaRetinitisEye Diseases
- Interventions
- Biological: Gene Therapy Product-MCO-010Procedure: Sham Injection
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04945772
- Locations
- ๐ต๐ท
Nanoscope Clinical Site, Arecibo, Puerto Rico
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
Phase 1
Completed
- Conditions
- Retinal DegenerationRetinal DiseasesRetinitis Pigmentosa
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Nanoscope Therapeutics Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04919473
- Locations
- ๐ฎ๐ณ
JPM Rotary Club of Cuttack Eye Hospital and Research Institute, Cuttack, Odisha, India
ยฉ Copyright 2025. All Rights Reserved by MedPath